Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Clinical trial NCT03711032 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03711032
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-24
- Primary completion
- 2026-07-31
- Enrollment
- 1397
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.